Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

Masahiro Toda, Samuel D. Rabkin, Hidefumi Kojima, Robert L. Martuza

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

The success of cancer gene therapy is likely to require the targeting of multiple antitumor mechanisms. One strategy involves the use of attenuated, replication-competent virus vectors, such as herpes simplex virus type 1 (HSV-1) mutant G207, which is able to replicate in human tumor cells with resultant cell death and tumor growth inhibition, yet is nonpathogenic in normal tissue. In this study, we demonstrate that infection of established tumors with G207 also induces a highly specific systemic anti-tumor immune response. In a syngeneic, bilateral established subcutaneous tumor model, with mouse CT26 colorectal carcinoma cells in BALB/c mice or M3 melanoma cells in DBA/2 mice, unilateral intratumoral inoculation with G207 caused a significant reduction in the growth of both the inoculated and contralateral noninoculated tumors. This elicited anti-tumor response is dependent on viral infection of the tumor, as intradermal inoculation of G207 in BALB/c mice had no effect on CT26 tumor growth. Treatment of subcutaneous CT26 tumors by intratumoral inoculation of G207 induced a tumor-specific T cell response, CD8+ cytotoxic T lymphocyte (CTL) activity was generated that recognized a dominant 'tumor-specific' major histocompatibility complex (MHC) class I-restricted epitope (AH1) from CT26 cells. In immune-competent animals, G207 is acting as an in situ tumor vaccine. Therefore, intratumoral G207 inoculation is able to inhibit tumor growth both by local cytotoxic viral replication in tumor cells and induction of a systemic anti-tumor immune response.

Original languageEnglish
Pages (from-to)385-393
Number of pages9
JournalHuman Gene Therapy
Volume10
Issue number3
DOIs
Publication statusPublished - 1999 Feb 10

Fingerprint

Cancer Vaccines
Simplexvirus
Immunity
Neoplasms
Growth
Inbred DBA Mouse
Neoplasm Genes
Human Herpesvirus 1
Cytotoxic T-Lymphocytes
Virus Diseases
Virus Replication
Major Histocompatibility Complex
Genetic Therapy

ASJC Scopus subject areas

  • Genetics

Cite this

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. / Toda, Masahiro; Rabkin, Samuel D.; Kojima, Hidefumi; Martuza, Robert L.

In: Human Gene Therapy, Vol. 10, No. 3, 10.02.1999, p. 385-393.

Research output: Contribution to journalArticle

Toda, Masahiro ; Rabkin, Samuel D. ; Kojima, Hidefumi ; Martuza, Robert L. / Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. In: Human Gene Therapy. 1999 ; Vol. 10, No. 3. pp. 385-393.
@article{4858f9b4b2f74aa39177aa46d3739f10,
title = "Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity",
abstract = "The success of cancer gene therapy is likely to require the targeting of multiple antitumor mechanisms. One strategy involves the use of attenuated, replication-competent virus vectors, such as herpes simplex virus type 1 (HSV-1) mutant G207, which is able to replicate in human tumor cells with resultant cell death and tumor growth inhibition, yet is nonpathogenic in normal tissue. In this study, we demonstrate that infection of established tumors with G207 also induces a highly specific systemic anti-tumor immune response. In a syngeneic, bilateral established subcutaneous tumor model, with mouse CT26 colorectal carcinoma cells in BALB/c mice or M3 melanoma cells in DBA/2 mice, unilateral intratumoral inoculation with G207 caused a significant reduction in the growth of both the inoculated and contralateral noninoculated tumors. This elicited anti-tumor response is dependent on viral infection of the tumor, as intradermal inoculation of G207 in BALB/c mice had no effect on CT26 tumor growth. Treatment of subcutaneous CT26 tumors by intratumoral inoculation of G207 induced a tumor-specific T cell response, CD8+ cytotoxic T lymphocyte (CTL) activity was generated that recognized a dominant 'tumor-specific' major histocompatibility complex (MHC) class I-restricted epitope (AH1) from CT26 cells. In immune-competent animals, G207 is acting as an in situ tumor vaccine. Therefore, intratumoral G207 inoculation is able to inhibit tumor growth both by local cytotoxic viral replication in tumor cells and induction of a systemic anti-tumor immune response.",
author = "Masahiro Toda and Rabkin, {Samuel D.} and Hidefumi Kojima and Martuza, {Robert L.}",
year = "1999",
month = "2",
day = "10",
doi = "10.1089/10430349950018832",
language = "English",
volume = "10",
pages = "385--393",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

AU - Toda, Masahiro

AU - Rabkin, Samuel D.

AU - Kojima, Hidefumi

AU - Martuza, Robert L.

PY - 1999/2/10

Y1 - 1999/2/10

N2 - The success of cancer gene therapy is likely to require the targeting of multiple antitumor mechanisms. One strategy involves the use of attenuated, replication-competent virus vectors, such as herpes simplex virus type 1 (HSV-1) mutant G207, which is able to replicate in human tumor cells with resultant cell death and tumor growth inhibition, yet is nonpathogenic in normal tissue. In this study, we demonstrate that infection of established tumors with G207 also induces a highly specific systemic anti-tumor immune response. In a syngeneic, bilateral established subcutaneous tumor model, with mouse CT26 colorectal carcinoma cells in BALB/c mice or M3 melanoma cells in DBA/2 mice, unilateral intratumoral inoculation with G207 caused a significant reduction in the growth of both the inoculated and contralateral noninoculated tumors. This elicited anti-tumor response is dependent on viral infection of the tumor, as intradermal inoculation of G207 in BALB/c mice had no effect on CT26 tumor growth. Treatment of subcutaneous CT26 tumors by intratumoral inoculation of G207 induced a tumor-specific T cell response, CD8+ cytotoxic T lymphocyte (CTL) activity was generated that recognized a dominant 'tumor-specific' major histocompatibility complex (MHC) class I-restricted epitope (AH1) from CT26 cells. In immune-competent animals, G207 is acting as an in situ tumor vaccine. Therefore, intratumoral G207 inoculation is able to inhibit tumor growth both by local cytotoxic viral replication in tumor cells and induction of a systemic anti-tumor immune response.

AB - The success of cancer gene therapy is likely to require the targeting of multiple antitumor mechanisms. One strategy involves the use of attenuated, replication-competent virus vectors, such as herpes simplex virus type 1 (HSV-1) mutant G207, which is able to replicate in human tumor cells with resultant cell death and tumor growth inhibition, yet is nonpathogenic in normal tissue. In this study, we demonstrate that infection of established tumors with G207 also induces a highly specific systemic anti-tumor immune response. In a syngeneic, bilateral established subcutaneous tumor model, with mouse CT26 colorectal carcinoma cells in BALB/c mice or M3 melanoma cells in DBA/2 mice, unilateral intratumoral inoculation with G207 caused a significant reduction in the growth of both the inoculated and contralateral noninoculated tumors. This elicited anti-tumor response is dependent on viral infection of the tumor, as intradermal inoculation of G207 in BALB/c mice had no effect on CT26 tumor growth. Treatment of subcutaneous CT26 tumors by intratumoral inoculation of G207 induced a tumor-specific T cell response, CD8+ cytotoxic T lymphocyte (CTL) activity was generated that recognized a dominant 'tumor-specific' major histocompatibility complex (MHC) class I-restricted epitope (AH1) from CT26 cells. In immune-competent animals, G207 is acting as an in situ tumor vaccine. Therefore, intratumoral G207 inoculation is able to inhibit tumor growth both by local cytotoxic viral replication in tumor cells and induction of a systemic anti-tumor immune response.

UR - http://www.scopus.com/inward/record.url?scp=0033540654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033540654&partnerID=8YFLogxK

U2 - 10.1089/10430349950018832

DO - 10.1089/10430349950018832

M3 - Article

C2 - 10048391

AN - SCOPUS:0033540654

VL - 10

SP - 385

EP - 393

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -